Gilead Sciences Company Profile (NASDAQ:GILD)

Analyst Ratings

Consensus Ratings for Gilead Sciences (NASDAQ:GILD) (?)
Ratings Breakdown: 10 Hold Rating(s), 16 Buy Rating(s), 2 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $108.32 (36.41% upside)

Analysts' Ratings History for Gilead Sciences (NASDAQ:GILD)
Show:
DateFirmActionRatingPrice TargetActions
7/29/2016ArgusDowngradeBuy -> Hold$88.00 -> $81.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2016Barclays PLCReiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2016Maxim GroupSet Price TargetHold$88.55View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2016BMO Capital MarketsReiterated RatingMarket Perform$97.00 -> $98.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/26/2016RBC Capital MarketsReiterated RatingOutperform$120.00 -> $105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/26/2016Credit Suisse Group AGReiterated RatingBuy$120.00 -> $115.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/26/2016Robert W. BairdReiterated RatingOutperform$135.00 -> $122.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/26/2016Piper Jaffray Cos.Lower Price TargetOverweight$114.00 -> $108.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/26/2016Jefferies GroupReiterated RatingHold$97.00 -> $93.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/26/2016Needham & Company LLCDowngradeBuy -> Hold$84.60 -> $88.55View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/26/2016Royal Bank Of CanadaLower Price TargetOutperform$120.00 -> $105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/5/2016Cowen and CompanyReiterated RatingOutperform$125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Leerink SwannReiterated RatingOutperform$127.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016Morgan StanleyReiterated RatingHold$103.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016GabelliInitiated CoverageBuy$109.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Citigroup Inc.Reiterated RatingBuy$105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Oppenheimer Holdings Inc.Reiterated RatingBuy$120.00 -> $116.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/10/2016MizuhoReiterated RatingBuy$130.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2016Bank of America Corp.Reiterated RatingNeutral$104.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman Sachs Group Inc.Lower Price Target$91.00 -> $87.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2016Evercore ISIReiterated RatingBuy$115.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2016Standpoint ResearchInitiated CoverageBuy$110.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/1/2016William BlairReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2016Wells Fargo & Co.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$111.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/10/2015Jyske BankUpgradeStrong-Buy$125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015Stifel NicolausDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2015Deutsche Bank AGBoost Price Target$125.00 -> $135.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2015Sanford C. BernsteinReiterated RatingOutperform$125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2015NomuraSet Price TargetBuy$141.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/31/2014Edward JonesInitiated CoverageHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/13/2014FBR & CoBoost Price TargetOutperform$125.00 -> $130.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Gilead Sciences (NASDAQ:GILD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
10/25/2016        
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115$2.32$2.94$6.81 billion$7.59 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/3/2015Q414$2.19$2.43$6.68 million$7.31 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2014Q214$1.73$2.36$5.68 billion$6.53 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/22/2014Q114$0.85$1.48$3.80 billion$5.00 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/23/2012$0.94$1.00ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/26/2012$0.95$0.99ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012$0.94$0.91ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2012$1.04$0.97ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2011$1.01$1.02ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/20/2011$0.97$0.87ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/25/2011$0.95$0.95ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Gilead Sciences (NASDAQ:GILD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$2.88$3.29$3.06
Q2 20162$3.03$3.25$3.14
Q3 20164$2.79$3.04$2.95
Q4 20163$2.85$3.01$2.92
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Gilead Sciences (NASDAQ:GILD)
Annual Dividend:$1.88
Dividend Yield:2.37%
Payout Ratio:16.56% (Based on Trailing 12 Months of Earnings)
16.32% (Based on Current Year Consensus EPS Estimate)
16.22% (Based on Next Year Consensus EPS Estimate)

Dividend History for Gilead Sciences (NASDAQ:GILD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
7/25/2016quarterly$0.472.32%9/14/20169/16/20169/29/2016Tweet This Announcement  Share This Announcement on StockTwits
4/28/2016quarterly$0.472.13%6/14/20166/16/20166/29/2016Tweet This Announcement  Share This Announcement on StockTwits
2/2/2016quarterly$0.431.99%3/14/20163/16/20163/30/2016Tweet This Announcement  Share This Announcement on StockTwits
10/27/2015quarterly$0.431.59%12/14/201512/16/201512/30/2015Tweet This Announcement  Share This Announcement on StockTwits
7/28/2015quarterly$0.431.49%9/14/20159/16/20159/29/2015Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015quarterly$0.436/12/20156/16/20156/29/2015Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Gilead Sciences (NASDAQ:GILD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.21View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Gilead Sciences (NASDAQ:GILD)
DateHeadline
07/30/16 07:06 AMHC Stocks Outlines: Gilead Sciences, Inc. (NASDAQ:GILD ... - share market updates (press release)
07/29/16 11:18 AMTop 5 Corporate Donors in Big Pharma (GILD, MRK)
07/29/16 11:18 AMGilead Sciences: A Hard Wind is Gonna Blow
07/29/16 10:58 AMBiotech Stocks: The End of Political Risk? -
07/29/16 10:40 AMMerck posts strong 2Q numbers, while building for long term -
07/29/16 10:15 AMWhy Key Analyst Sees More Headwinds for Gilead Sciences -
07/28/16 03:00 PMWould Gilead Sciences, Inc. (GILD) Be Able to Survive Without Eminent HCV Franchise?
07/28/16 12:49 PMU.S. biotech stocks win back investors in big July run -
07/28/16 07:06 AMGilead Sciences Inc A Great Opportunity Post Q2 Earnings - Amigobulls
07/28/16 02:18 AMDMG MORI still meeting target forecasts Annual forecast 2016 reconfirmed in volatile market environment - [at noodls] - July 28, 2016 Sales revenues amounted to € 1,092.5 million (previous year: € 1,090.2 million) Order intake reached € 1,158.2 million (previous year: € 1,203.3 million) EBT was € 61.2 million (previous ...
07/27/16 06:01 PMUK health service under fire over access to hepatitis C drugs - [Reuters - UK Focus] - British health authorities improperly restrict access to expensive new hepatitis C drugs that can cure the liver-destroying disease, patient groups and a leading medical journal charged on Thursday. Despite the clear benefits of the drugs, the National Health Service in England rations the drugs to just 10,000 people with the virus each year, campaigners said. The Hepatitis C Trust said it was now seeking a judicial review of NHS England's decision and the court is considering whether to grant permission for the case to go ahead.
07/27/16 04:27 PMMaxim Anayst Raises Concerns for Gilead Sciences, Inc. (GILD) Following 2Q Earnings - Smarter Analyst
07/27/16 04:08 PMGilead Sciences Is Still a Buy -
07/27/16 02:33 PMGilead's Valuation Makes It a Screaming Buy -
07/27/16 04:19 AMNews Buzz - Gilead Sciences, Inc.(NASDAQ:GILD), JetBlue Airways Corporation(NASDAQ:JBLU) - NYSE Journal (press release)
07/27/16 04:19 AMAnalysts Trends to Watch: Gilead Sciences, Inc. (NASDAQ:GILD) , Thermo Fisher Scientific Inc (NYSE:TMO) - Street Updates
07/26/16 10:27 PMEyes Catching Biotech Stocks in Verities- Gilead Sciences (NASDAQ:GILD), Celgene (NASDAQ:CELG) - Seneca Globe
07/26/16 10:27 PMGilead Sciences, Inc. (NASDAQ:GILD) & Relypsa Inc (NASDAQ:RLYP) Hot Stock's Alert - Money News (press release)
07/26/16 10:27 PMAnalysts Rating updates about two Stocks: Gilead Sciences, Inc. (NASDAQ:GILD) , Edwards Lifesciences Corporation ... - Street Updates
07/26/16 10:27 PMGilead Sciences Inc. Earnings Decline 14% In Q2 - Nasdaq
07/26/16 10:27 PMGilead Sciences Inc. (GILD) Falls 8.47% for July 26 - Equities.com
07/26/16 04:24 PMGilead Sciences, Inc. (GILD) Gets Price Target Trimmed Following Guidance Adjustments
07/26/16 04:24 PMGilead (GILD) Beats on Q2 Earnings, Cuts 2016 Sales View
07/26/16 04:24 PMGilead Sciences Inc. (GILD) Is Falling After Guidance Lowered
07/26/16 04:24 PMGILD, MBLY and UA stock used more than their fair share of red ink on Tuesday
07/26/16 02:51 PMHarvoni Sales Declines Hurt Gilead Sciences Inc. in Q2 - Disappointing revenue and earnings for this big biotech stem from big drops in sales for its top drug, Harvoni.
07/26/16 11:49 AM3 Key Takeaways Following Gilead Sciences' Second-Quarter Conference Call - Struggles in oncology and hepatitis C are overshadowing growth in HIV treatment. Gilead Sciences' troubles, however, could be short-term if its R&D program pans out.
07/26/16 09:58 AMGilead Sciences, Inc. (GILD): Catch This Falling Knife NOW - <p><a rel="nofollow" href="http://investorplace.com">InvestorPlace</a><a rel="nofollow" href="http://investorplace.com">InvestorPlace - Stock Market News, Stock Advice & Trading Tips</a></p> <p>GILD stock was hit hard on Tuesday, continuing the pain for healthcare. But I see Gilead Sciences as an opportunity to pounce on.</p> <p>The post <a rel="nofollow" href="http://investorplace.com/2016/07/gilead-sciences-gild-stock-knife/">Gilead Sciences, Inc. (GILD): Catch This Falling Knife NOW</a> appeared first on <a rel="nofollow" href="http://investorplace.com">InvestorPlace</a>.</p>
07/26/16 08:45 AM3 Big Stock Charts for Tuesday: AbbVie Inc (ABBV), Gilead Sciences, Inc. (GILD) and Sprint Corp (S) - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie (ABBV), Gilead (GILD) and Sprint (S) are all moving today after their respective earnings reports. All three have additional profit potential for those queued into these technical pictures. The post 3 Big Stock Charts for Tuesday: AbbVie Inc (ABBV), Gilead Sciences, Inc. (GILD) and Sprint Corp (S) appeared first on InvestorPlace.
07/26/16 07:03 AMNoteworthy Analyst Rating of Gilead Sciences, Inc. (NASDAQ:GILD) - The Voice Registrar
07/26/16 07:03 AMBiotech Titan on Spike: Gilead Sciences Inc. (NASDAQ:GILD) Beats Wall Street Expectations Once Again- AbbVie Inc ... - Seneca Globe
07/26/16 07:03 AMPrice Target Review: Gilead Sciences Inc. (GILD) - News Oracle
07/26/16 06:41 AMStock Futures Flat as Federal Reserve Prepares to Meet -
07/26/16 06:37 AMWait On The DNC Before Going Long Biotech ETFs - This week is a potentially troublesome one for biotechnology stocks and the related exchange traded funds. Not only are there a spate of big-name biotech earnings scheduled to roll in, but the Democratic National Convention is taking place in Philadelphia. Gilead Sciences, Inc. (NASDAQ: GILD) got the earnings ball rolling after Monday's close and investors weren't pleased by the company's guidance. Combine that with the fact that political volatility has been widely cited as a problem for the biotech sector dating back to last year, and it's easy to see why some market participants are waiting for this week's convention to conclude before initiating new long positions in ETFs such as the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB). Related ...Full story available on Benzinga.com
07/26/16 05:55 AMGilead cuts 2016 sales forecast, cites hepatitis C drugs - Gilead Sciences lowered its full-year sales outlook, citing slower-than-expected demand for its hepatitis C drugs, and said profits fell 22 percent.
07/25/16 09:42 PM7 Key Figures From Gilead Sciences' Q2 Earnings - Motley Fool - Motley Fool7 Key Figures From Gilead Sciences' Q2 EarningsMotley FoolGilead Sciences, Inc. (NASDAQ:GILD) is one of the biggest companies in biopharma, but that hasn't kept investors from selling its shares this year. Stiffening competition in the market for hepatitis C treatment has caused sales of its multibillion ...Gilead cuts 2016 sales forecast, cites hepatitis C drugsReutersGilead Is Back To Beating EstimatesSeeking AlphaGilead's high-flying hep C franchise comes down to earth, forcing a cut to 2016 guidanceFiercePharmaNasdaq -24/7 Wall St. -Investorplace.com -Investor's Business Dailyall 76 news articles »
07/25/16 09:23 PM7 Key Figures From Gilead Sciences' Q2 Earnings - Gilead Sciences' Harvoni sales weighed on results, but the company's balance sheet strengthened.
07/25/16 05:40 PM4 Stocks Moving In Monday's After-Hours Session - U.S. stock markets closed down on Monday, accompanying oil prices, and ahead of a long slate of earnings calls and the Fed’s decision on interest rates. Sophiris Bio Inc (NASDAQ: SPHS) rose 35.84 percent during the regular session, and continued to rise more than 5.2 percent in the after-hours session. No particular news seemed to be driving said spike, which looked like a technical move. Shares of Gilead Sciences, Inc. (NASDAQ: GILD) traded down ...Full story available on Benzinga.com
07/25/16 04:43 PMGilead second-quarter net profit falls 22 percent - July 25 (Reuters) - Gilead Sciences Inc said on Monday its second-quarter net profit fell 22 percent, due mostly to lower sales of its hepatitis C drug Harvoni.
07/25/16 04:43 PMUPDATE 1-Gilead cuts 2016 sales forecast, cites hepatitis C drugs - July 25 (Reuters) - Gilead Sciences Inc on Monday lowered its full-year sales outlook, citing slower-than-expected sales of its key hepatitis C drugs, and said second-quarter profits fell 22 percent.
07/25/16 04:25 PMGilead Misses Revenue Estimates, Cuts Guidance - Gilead Sciences, Inc. (NASDAQ: GILD) released its Q2 results after market close on Monday. Revenues came in above Wall Street consensus expectations, however, the company lowered sales guidance, sending shares down 4 percent. Gilead reported EPS of $3.08 and revenues of $7.776 billion. Analyst consensus had an EPS estimate ...Full story available on Benzinga.com
07/25/16 04:17 PMHC Trending Hot Stocks: Medtronic PLC (NYSE:MDT) Gilead Sciences, Inc. (NASDAQ:GILD) - share market updates (press release)
07/25/16 04:17 PMToday's Stocks: MGIC Investment Corp. (NYSE:MTG), Gilead Sciences Inc. (NASDAQ:GILD), Crown Castle ... - KC Register
07/25/16 04:17 PMMix Momentum Detain Active Stocks: Gilead Sciences Inc. (NASDAQ:GILD), Gentex Corp. (NASDAQ:GNTX), Merck ... - Seneca Globe
07/25/16 04:17 PMBaird's 2Q Earnings Preview: Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG) - Smarter Analyst
07/25/16 04:02 PMGILEAD SCIENCES INC Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial Statements and Exh -
07/25/16 03:50 PM[$$] Gilead Sales of Hepatitis C Drugs Fall 19% -
07/25/16 03:44 PMBRIEF-Gilead Sciences Q2 non-GAAP earnings per share $3.08 - * Q2 Harvoni sales $ 2.56 billion versus $3.61 billion last year
07/25/16 03:44 PMBRIEF-Gilead Sciences sets qtrly dividend of $0.47 per share - * Sets quarterly cash dividend of $0.47per share Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
07/25/16 03:37 PMAfter The Close: Gilead, Las Vegas Sands, Texas Instruments Earnings -

Social

About Gilead Sciences

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: GILD
  • CUSIP: 37555810
Key Metrics:
  • Previous Close: $81.24
  • 50 Day Moving Average: $84.02
  • 200 Day Moving Average: $88.46
  • P/E Ratio: 6.97
  • P/E Growth: 86.75
  • Market Cap: $105.77B
  • Beta: 1.09
  • Current Year EPS Consensus Estimate: $11.52 EPS
  • Next Year EPS Consensus Estimate: $11.59 EPS
Additional Links:
Gilead Sciences (NASDAQ:GILD) Chart for Saturday, July, 30, 2016